{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:39:59Z","timestamp":1775543999436,"version":"3.50.1"},"publisher-location":"Cham","reference-count":192,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031261626","type":"print"},{"value":"9783031261633","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-26163-3_2","type":"book-chapter","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:03:29Z","timestamp":1682323409000},"page":"25-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence"],"prefix":"10.1007","author":[{"given":"Yolanda","family":"Prado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Aravena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe M.","family":"Llancalahuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristobal","family":"Aravena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Eltit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Echeverr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Gatica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia A.","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"1","key":"2_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2003-38328","volume":"3","author":"KM Sere","year":"2003","unstructured":"Sere KM, Hackeng TM (2003) Basic mechanisms of hemostasis. Semin Vasc Med. 3(1):3\u201312","journal-title":"Semin Vasc Med."},{"issue":"3","key":"2_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF02591649","volume":"21","author":"N Semeraro","year":"1992","unstructured":"Semeraro N, Colucci M (1992) Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: role in disseminated intravascular coagulation associated with infectious diseases. Int J Clin Lab Res 21(3):214\u2013220","journal-title":"Int J Clin Lab Res"},{"issue":"5","key":"2_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1213\/ane.0b013e31819bcc9c","volume":"108","author":"KA Tanaka","year":"2009","unstructured":"Tanaka KA, Key NS, Levy JH (2009) Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 108(5):1433\u20131446","journal-title":"Anesth Analg"},{"issue":"5","key":"2_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1179\/acb.2006.036","volume":"61","author":"P Verhamme","year":"2006","unstructured":"Verhamme P, Hoylaerts MF (2006) The pivotal role of the endothelium in haemostasis and thrombosis. Acta Clin Belg 61(5):213\u2013219","journal-title":"Acta Clin Belg"},{"key":"2_CR5","doi-asserted-by":"crossref","unstructured":"Bouvy C, Gheldof D, Chatelain C, Mullier F, Dogne JM (2014) Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer. J Extracell Vesicles 3","DOI":"10.3402\/jev.v3.24400"},{"issue":"3","key":"2_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/10739680590925628","volume":"12","author":"MG Egbrink","year":"2005","unstructured":"Egbrink MG, Van Gestel MA, Broeders MA, Tangelder GJ, Heemskerk JM, Reneman RS et al (2005) Regulation of microvascular thromboembolism in vivo. Microcirculation 12(3):287\u2013300","journal-title":"Microcirculation"},{"key":"2_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.773027","volume":"9","author":"D Ganesh","year":"2021","unstructured":"Ganesh D, Jain P, Shanthamurthy CD, Toraskar S, Kikkeri R (2021) Targeting selectins mediated biological activities with multivalent probes. Front Chem 9:773027","journal-title":"Front Chem"},{"issue":"9","key":"2_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","volume":"18","author":"K Stark","year":"2021","unstructured":"Stark K, Massberg S (2021) Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol 18(9):666\u2013682","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"2_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/MOH.0000000000000551","volume":"27","author":"L Nicolai","year":"2020","unstructured":"Nicolai L, Massberg S (2020) Platelets as key players in inflammation and infection. Curr Opin Hematol 27(1):34\u201340","journal-title":"Curr Opin Hematol"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/asheducation-2015.1.243","volume":"2015","author":"JL Kujovich","year":"2015","unstructured":"Kujovich JL (2015) Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program 2015:243\u2013249","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.thromres.2022.03.013","volume":"213","author":"N Boknas","year":"2022","unstructured":"Boknas N, Laine C, Hillarp A, Macwan AS, Gustafsson KM, Lindahl TL et al (2022) Associations between hemostatic markers and mortality in COVID-19\u2014compounding effects of D-dimer, antithrombin and PAP complex. Thromb Res 213:97\u2013104","journal-title":"Thromb Res"},{"issue":"2","key":"2_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12664-019-00948-5","volume":"38","author":"S Arientova","year":"2019","unstructured":"Arientova S, Beran O, Chalupa P, Korinkova M, Holub M (2019) Antithrombin as a marker of severe acute hepatitis B. Indian J Gastroenterol 38(2):143\u2013149","journal-title":"Indian J Gastroenterol"},{"key":"2_CR13","doi-asserted-by":"crossref","unstructured":"Abo-Elenein AM, Mabrouk MM, Abou-Saif S, Saeed OM, Khodeir S, Elkadeem M et al (2020) Role of both protein C and antithrombin III as predictors of stage of liver disease in chronic viral hepatitis B or C infected patients. Endocr Metab Immune Disord Drug Targets 20(1):112\u2013117","DOI":"10.2174\/1871530319666190529092555"},{"issue":"4","key":"2_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002994","volume":"90","author":"MMS Sim","year":"2022","unstructured":"Sim MMS, Banerjee M, Myint T, Garvy BA, Whiteheart SW, Wood JP (2022) Total plasma protein S is a prothrombotic marker in people living with HIV. J Acquir Immune Defic Syndr 90(4):463\u2013471","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"2_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/15513815.2019.1587118","volume":"38","author":"N Samra","year":"2019","unstructured":"Samra N, AlGhwass M, Elgawhary S, Hassan M, Bekhit O, Mohamed W et al (2019) Serum level of antithrombin III (ATIII) could serve as a prognostic biomarker in neonatal sepsis. Fetal Pediatr Pathol 38(4):290\u2013298","journal-title":"Fetal Pediatr Pathol"},{"issue":"1","key":"2_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0300060516677929","volume":"45","author":"N Yang","year":"2017","unstructured":"Yang N, Hao J, Zhang D (2017) Antithrombin III and D-dimer levels as indicators of disease severity in patients with hyperlipidaemic or biliary acute pancreatitis. J Int Med Res 45(1):147\u2013158","journal-title":"J Int Med Res"},{"issue":"23","key":"2_CR17","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.3748\/wjg.v20.i23.7461","volume":"20","author":"HL He","year":"2014","unstructured":"He HL, Zhang JB, Li Q (2014) Clinical significance of expression of tissue factor and tissue factor pathway inhibitor in ulcerative colitis. World J Gastroenterol 20(23):7461","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/mco.2021.2479","volume":"16","author":"R Miyake","year":"2022","unstructured":"Miyake R, Yamada Y, Yamanaka S, Kawaguchi R, Ootake N, Myoba S et al (2022) Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results. Mol Clin Oncol 16(2):46","journal-title":"Mol Clin Oncol"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"8983763","DOI":"10.1155\/2017\/8983763","volume":"2017","author":"X Fei","year":"2017","unstructured":"Fei X, Wang H, Yuan W, Wo M, Jiang L (2017) Tissue factor pathway inhibitor-1 is a valuable marker for the prediction of deep venous thrombosis and tumor metastasis in patients with lung cancer. Biomed Res Int 2017:8983763","journal-title":"Biomed Res Int"},{"issue":"2","key":"2_CR20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11239-021-02457-9","volume":"52","author":"A Marco","year":"2021","unstructured":"Marco A, Marco P (2021) Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. J Thromb Thrombolysis 52(2):497\u2013503","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10456-020-09762-6","volume":"24","author":"A Philippe","year":"2021","unstructured":"Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N et al (2021) Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 24(3):505\u2013517","journal-title":"Angiogenesis"},{"key":"2_CR22","doi-asserted-by":"crossref","unstructured":"Watany MM, Abdou S, Elkolaly R, Elgharbawy N, Hodeib H (2022) Correction to: evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin Exp Med","DOI":"10.1007\/s10238-022-00802-7"},{"issue":"10","key":"2_CR23","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/ATVBAHA.120.314860","volume":"40","author":"S Nagashima","year":"2020","unstructured":"Nagashima S, Mendes MC, Camargo Martins AP, Borges NH, Godoy TM, Miggiolaro A et al (2020) Endothelial dysfunction and thrombosis in patients with COVID-19-brief report. Arterioscler Thromb Vasc Biol 40(10):2404\u20132407","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2_CR24","doi-asserted-by":"crossref","unstructured":"Birnhuber A, Fliesser E, Gorkiewicz G, Zacharias M, Seeliger B, David S et al (2021) Between inflammation and thrombosis: endothelial cells in COVID-19. Eur Respir J 58(3)","DOI":"10.1183\/13993003.00377-2021"},{"issue":"3","key":"2_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.thromres.2011.10.010","volume":"129","author":"C Cerletti","year":"2012","unstructured":"Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G (2012) Platelet\u2013leukocyte interactions in thrombosis. Thromb Res 129(3):263\u2013266","journal-title":"Thromb Res"},{"issue":"1","key":"2_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12933-018-0783-z","volume":"17","author":"L Pretorius","year":"2018","unstructured":"Pretorius L, Thomson GJA, Adams RCM, Nell TA, Laubscher WA, Pretorius E (2018) Platelet activity and hypercoagulation in type 2 diabetes. Cardiovasc Diabetol 17(1):141","journal-title":"Cardiovasc Diabetol"},{"issue":"21","key":"2_CR27","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019000518","volume":"134","author":"C Marx","year":"2019","unstructured":"Marx C, Novotny J, Salbeck D, Zellner KR, Nicolai L, Pekayvaz K et al (2019) Eosinophil\u2013platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood 134(21):1859\u20131872","journal-title":"Blood"},{"issue":"2","key":"2_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ana.24993","volume":"82","author":"E Laridan","year":"2017","unstructured":"Laridan E, Denorme F, Desender L, Francois O, Andersson T, Deckmyn H et al (2017) Neutrophil extracellular traps in ischemic stroke thrombi. Ann Neurol 82(2):223\u2013232","journal-title":"Ann Neurol"},{"issue":"4","key":"2_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1708538120915997","volume":"28","author":"A Zamzam","year":"2020","unstructured":"Zamzam A, Syed MH, Rand ML, Singh K, Hussain MA, Jain S et al (2020) Altered coagulation profile in peripheral artery disease patients. Vascular 28(4):368\u2013377","journal-title":"Vascular"},{"issue":"2","key":"2_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1213\/ANE.0b013e31822e1853","volume":"114","author":"JH Levy","year":"2012","unstructured":"Levy JH, Szlam F, Tanaka KA, Sniecienski RM (2012) Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 114(2):261\u2013274","journal-title":"Anesth Analg"},{"issue":"2","key":"2_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1538-7836.2007.02297.x","volume":"5","author":"B Charbit","year":"2007","unstructured":"Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H et al (2007) The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 5(2):266\u2013273","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.thromres.2008.04.004","volume":"123","author":"J Shen","year":"2009","unstructured":"Shen J, Ran ZH, Zhang Y, Cai Q, Yin HM, Zhou XT et al (2009) Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified, cohort analysis. Thromb Res 123(4):604\u2013611","journal-title":"Thromb Res"},{"key":"2_CR33","doi-asserted-by":"crossref","unstructured":"Panova-Noeva M, Schulz A, Arnold N, Hermanns MI, Prochaska JH, Laubert-Reh D et al (2018) Coagulation and inflammation in long-term cancer survivors: results from the adult population. J Thromb Haemost 16(4):699\u2013708","DOI":"10.1111\/jth.13975"},{"issue":"3","key":"2_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/00365513.2019.1709986","volume":"80","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Mao M, Meng J, Shi K, Lin J, Lu Q (2020) The thromboelastography G parameter as a potential biomarker of acute coronary syndrome. Scand J Clin Lab Invest 80(3):196\u2013201","journal-title":"Scand J Clin Lab Invest"},{"key":"2_CR35","doi-asserted-by":"crossref","unstructured":"Gebbink MF (2011) Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 9(Suppl 1):174\u2013181","DOI":"10.1111\/j.1538-7836.2011.04278.x"},{"issue":"10","key":"2_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJM198403083101001","volume":"310","author":"F Van de Werf","year":"1984","unstructured":"Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, de Geest H et al (1984) Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 310(10):609\u2013613","journal-title":"N Engl J Med"},{"issue":"1","key":"2_CR37","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41598-020-80010-z","volume":"11","author":"Y Zuo","year":"2021","unstructured":"Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M et al (2021) Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 11(1):1580","journal-title":"Sci Rep"},{"issue":"5","key":"2_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.thromres.2008.07.015","volume":"123","author":"D Sahli","year":"2009","unstructured":"Sahli D, Eriksson JW, Boman K, Svensson MK (2009) Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res 123(5):701\u2013706","journal-title":"Thromb Res"},{"key":"2_CR39","doi-asserted-by":"crossref","unstructured":"Flores J, Garcia-Avello A, Alonso E, Ruiz A, Navarrete O, Alvarez C et al (2014) Tissue plasminogen activator as a novel diagnostic aid in acute pulmonary embolism. Vasa 43(6):450\u2013458","DOI":"10.1024\/0301-1526\/a000392"},{"issue":"8","key":"2_CR40","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00018-019-03005-8","volume":"76","author":"J Zhu","year":"2019","unstructured":"Zhu J, Wan Y, Xu H, Wu Y, Hu B, Jin H (2019) The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe? Cell Mol Life Sci 76(8):1489\u20131506","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2_CR41","first-page":"29","volume":"62","author":"F Lachatre","year":"2007","unstructured":"Lachatre F, Gothot A (2007) Clinical use of D-dimer testing. Rev Med Liege 62(1):29\u201335","journal-title":"Rev Med Liege"},{"key":"2_CR42","doi-asserted-by":"crossref","unstructured":"Hosseini SF, Behnam-Roudsari S, Alavinia G, Emami A, Toghyani A, Moradi S et al (2021) Diagnostic and prognostic value of sepsis-induced coagulopathy and international society on thrombosis and hemostasis scoring systems in COVID-19-associated disseminated intravascular coagulopathy. J Res Med Sci 26:102","DOI":"10.4103\/jrms.JRMS_1295_20"},{"issue":"10","key":"2_CR43","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1507\/endocrj.EJ14-0102","volume":"61","author":"H Fukuoka","year":"2014","unstructured":"Fukuoka H, Takeuchi T, Matsumoto R, Bando H, Suda K, Nishizawa H et al (2014) D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing\u2019s syndrome. Endocr J 61(10):1003\u20131010","journal-title":"Endocr J"},{"issue":"1","key":"2_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1076029615588784","volume":"23","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zan P, Gong J, Cai M (2017) d-Dimer as a screening marker for venous thromboembolism after surgery among patients younger than 50 with lower limb fractures. Clin Appl Thromb Hemost 23(1):78\u201383","journal-title":"Clin Appl Thromb Hemost"},{"key":"2_CR45","doi-asserted-by":"crossref","unstructured":"Marcq G, Beaugrand Dubart L, Tournoys A, Subtil D, Deruelle P (2014) Evaluation of D-dimer as a marker for severity in pregnancies with preeclampsia. Gynecol Obstet Fertil 42(6):393\u2013398","DOI":"10.1016\/j.gyobfe.2012.09.019"},{"issue":"29","key":"2_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000270","volume":"93","author":"S Yang","year":"2014","unstructured":"Yang S, Fan X, Ding W, Liu B, Meng J, Wang K et al (2014) D-dimer as an early marker of severity in patients with acute superior mesenteric venous thrombosis. Medicine (Baltimore) 93(29):e270","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00534-011-0414-5","volume":"19","author":"L Ke","year":"2012","unstructured":"Ke L, Ni HB, Tong ZH, Li WQ, Li N, Li JS (2012) D-dimer as a marker of severity in patients with severe acute pancreatitis. J Hepatobiliary Pancreat Sci 19(3):259\u2013265","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2_CR48","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ajem.2020.12.023","volume":"40","author":"M Ozen","year":"2021","unstructured":"Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M et al (2021) D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med 40:55\u201359","journal-title":"Am J Emerg Med"},{"issue":"6","key":"2_CR49","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jth.14859","volume":"18","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z et al (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18(6):1324\u20131329","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL (2021) Global epidemiology of dyslipidaemias. Nat Rev Cardiol 18(10):689\u2013700","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"2_CR51","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1080\/14656566.2021.1912734","volume":"22","author":"B Tomlinson","year":"2021","unstructured":"Tomlinson B, Patil NG, Fok M, Lam CWK (2021) Managing dyslipidemia in patients with type 2 diabetes. Expert Opin Pharmacother 22(16):2221\u20132234","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"2_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ccl.2021.04.008","volume":"39","author":"A Thobani","year":"2021","unstructured":"Thobani A, Jacobson TA (2021) Dyslipidemia in patients with kidney disease. Cardiol Clin 39(3):353\u2013363","journal-title":"Cardiol Clin"},{"issue":"8","key":"2_CR53","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS (2016) Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism 65(8):1109\u20131123","journal-title":"Metabolism"},{"issue":"3","key":"2_CR54","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5937\/jomb0-27106","volume":"40","author":"I Spasic","year":"2021","unstructured":"Spasic I, Ubavic M, Sumarac Z, Todorovic M, Vuckovic B (2021) Influence of lipid metabolism disorders on venous thrombosis risk. J Med Biochem 40(3):245\u2013251","journal-title":"J Med Biochem"},{"key":"2_CR55","doi-asserted-by":"crossref","unstructured":"Carmena R, Duriez P, Fruchart JC (2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation 109(23 Suppl 1):III2\u2013III7","DOI":"10.1161\/01.CIR.0000131511.50734.44"},{"key":"2_CR56","first-page":"35","volume":"73\u201374","author":"E Rannou","year":"1987","unstructured":"Rannou E (1987) A concrete case: celioscopy in the exploration of a left latero-uterine mass associated with pelvic pain and delayed menses. Soins Gynecol Obstet Pueric Pediatr 73\u201374:35\u201336","journal-title":"Soins Gynecol Obstet Pueric Pediatr"},{"key":"2_CR57","doi-asserted-by":"crossref","unstructured":"Poropat Flerin T, Bozic Mijovski M, Jug B (2022) Association between lipoprotein subfractions, hemostatic potentials, and coronary atherosclerosis. Dis Markers 2022:2993309","DOI":"10.1155\/2022\/2993309"},{"issue":"2","key":"2_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2174\/1567202611666140307104724","volume":"11","author":"CN Ferreira","year":"2014","unstructured":"Ferreira CN, Carvalho MG, Reis HJ, Gomes KB, Sousa MO, Palotas A (2014) Hyper-coagulable profile with elevated pro-thrombotic biomarkers and increased cerebro- and cardio-vascular disease risk exist among healthy dyslipidemic women. Curr Neurovasc Res 11(2):142\u2013148","journal-title":"Curr Neurovasc Res"},{"issue":"1","key":"2_CR59","doi-asserted-by":"publisher","first-page":"12952","DOI":"10.1038\/s41598-022-17421-7","volume":"12","author":"X Jia","year":"2022","unstructured":"Jia X, Zhang X, Sun D, Yang N, Li R, Luo Z (2022) Triglyceride to HDL-C ratio is associated with plasma D-dimer levels in different types of pancreatitis. Sci Rep 12(1):12952","journal-title":"Sci Rep"},{"issue":"2","key":"2_CR60","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s11239-017-1594-x","volume":"45","author":"S Ebara","year":"2018","unstructured":"Ebara S, Marumo M, Mukai J, Ohki M, Uchida K, Wakabayashi I (2018) Relationships of oxidized HDL with blood coagulation and fibrinolysis in patients with type 2 diabetes mellitus. J Thromb Thrombolysis 45(2):200\u2013205","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.atherosclerosis.2010.05.010","volume":"212","author":"A Assinger","year":"2010","unstructured":"Assinger A, Koller F, Schmid W, Zellner M, Babeluk R, Koller E et al (2010) Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects. Atherosclerosis 212(1):153\u2013160","journal-title":"Atherosclerosis"},{"key":"2_CR62","doi-asserted-by":"crossref","unstructured":"de Laat-Kremers R, Di Castelnuovo A, van der Vorm L, Costanzo S, Ninivaggi M, Cerletti C et al (2022) Increased BMI and blood lipids are associated with a hypercoagulable state in the Moli-sani cohort. Front Cardiovasc Med 9:897733","DOI":"10.3389\/fcvm.2022.897733"},{"issue":"1","key":"2_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11239-010-0474-4","volume":"31","author":"D Karasek","year":"2011","unstructured":"Karasek D, Vaverkova H, Halenka M, Jackuliakova D, Frysak Z, Slavik L et al (2011) Prothrombotic markers in asymptomatic dyslipidemic subjects. J Thromb Thrombolysis 31(1):27\u201336","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2_CR64","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1203\/01.PDR.0000112098.64368.8A","volume":"55","author":"M Albisetti","year":"2004","unstructured":"Albisetti M, Chan AK, McCrindle BW, Wong D, Monagle P, Andrew M (2004) Impaired fibrinolytic activity is present in children with dyslipidemias. Pediatr Res 55(4):576\u2013580","journal-title":"Pediatr Res"},{"issue":"1","key":"2_CR65","first-page":"69","volume":"17","author":"F Cernecca","year":"1995","unstructured":"Cernecca F, Peratoner L, Simeone R, Barbi E, Cattin L (1995) Dyslipidemia and reduced fibrinolysis in a child with hemolytic-uremic syndrome. Pediatr Med Chir 17(1):69\u201371","journal-title":"Pediatr Med Chir"},{"issue":"3","key":"2_CR66","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/CNQ.0000000000000157","volume":"40","author":"RS Sharara","year":"2017","unstructured":"Sharara RS, Hattab Y, Patel K, DiSilvio B, Singh AC, Malik K (2017) Introduction to the anatomy and physiology of pulmonary circulation. Crit Care Nurs Q 40(3):181\u2013190","journal-title":"Crit Care Nurs Q"},{"issue":"19","key":"2_CR67","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1007\/s00018-019-03100-w","volume":"76","author":"SN Chang","year":"2019","unstructured":"Chang SN, Wu CK, Lai LP, Chiang FT, Hwang JJ, Tsai CT (2019) The effect and molecular mechanism of statins on the expression of human anti-coagulation genes. Cell Mol Life Sci 76(19):3891\u20133898","journal-title":"Cell Mol Life Sci"},{"key":"2_CR68","doi-asserted-by":"crossref","unstructured":"Tonkin A, Byrnes A (2014) Treatment of dyslipidemia. F1000Prime Rep 6:17","DOI":"10.12703\/P6-17"},{"issue":"1","key":"2_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","volume":"40","author":"W Jiang","year":"2021","unstructured":"Jiang W, Hu JW, He XR, Jin WL, He XY (2021) Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res 40(1):241","journal-title":"J Exp Clin Cancer Res"},{"key":"2_CR70","doi-asserted-by":"crossref","unstructured":"Valentovic M (2007) Lovastatin. Elsevier","DOI":"10.1016\/B978-008055232-3.62056-2"},{"key":"2_CR71","unstructured":"Duong H, Bajaj T (2022) Lovastatin. StatPearls, Treasure Island, FL"},{"key":"2_CR72","unstructured":"Talreja O, Kerndt CC, Cassagnol M (2022) Simvastatin. StatPearls, Treasure Island, FL"},{"issue":"9","key":"2_CR73","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/1096-9888(200009)35:9<1133::AID-JMS42>3.0.CO;2-X","volume":"35","author":"JJ Zhao","year":"2000","unstructured":"Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD (2000) Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography\/tandem mass spectrometry. J Mass Spectrom 35(9):1133\u20131143","journal-title":"J Mass Spectrom"},{"issue":"12","key":"2_CR74","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","volume":"29","author":"A Endo","year":"1976","unstructured":"Endo A, Kuroda M, Tsujita Y (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 29(12):1346\u20131348","journal-title":"J Antibiot (Tokyo)"},{"issue":"5","key":"2_CR75","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00253-002-0932-9","volume":"58","author":"M Manzoni","year":"2002","unstructured":"Manzoni M, Rollini M (2002) Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 58(5):555\u2013564","journal-title":"Appl Microbiol Biotechnol"},{"issue":"2","key":"2_CR76","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","volume":"124","author":"NC Ward","year":"2019","unstructured":"Ward NC, Watts GF, Eckel RH (2019) Statin toxicity. Circ Res 124(2):328\u2013350","journal-title":"Circ Res"},{"key":"2_CR77","doi-asserted-by":"crossref","unstructured":"Reig-Lopez J, Garcia-Arieta A, Mangas-Sanjuan V, Merino-Sanjuan M (2021) Current evidence, challenges, and opportunities of physiologically based pharmacokinetic models of atorvastatin for decision making. Pharmaceutics 13(5)","DOI":"10.3390\/pharmaceutics13050709"},{"key":"2_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4137\/CMC.S4324","volume":"6","author":"A Luvai","year":"2012","unstructured":"Luvai A, Mbagaya W, Hall AS, Barth JH (2012) Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin Med Insights Cardiol 6:17\u201333","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"2_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19(1):117\u2013125","journal-title":"Fundam Clin Pharmacol"},{"key":"2_CR80","unstructured":"Bajaj T, Giwa AO (2022) Rosuvastatin. StatPearls, Treasure Island, FL"},{"issue":"3","key":"2_CR81","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1527-3466.2003.tb00116.x","volume":"21","author":"K Kajinami","year":"2003","unstructured":"Kajinami K, Takekoshi N, Saito Y (2003) Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 21(3):199\u2013215","journal-title":"Cardiovasc Drug Rev"},{"issue":"1","key":"2_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/14656566.2018.1544243","volume":"20","author":"P Chan","year":"2019","unstructured":"Chan P, Shao L, Tomlinson B, Zhang Y, Liu ZM (2019) An evaluation of pitavastatin for the treatment of hypercholesterolemia. Expert Opin Pharmacother 20(1):103\u2013113","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2_CR83","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40256-017-0213-8","volume":"17","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs 17(2):157\u2013168","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"2_CR84","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1208\/ps020326","volume":"2","author":"A Lindahl","year":"2000","unstructured":"Lindahl A, Frid S, Ungell AL, Lennernas H (2000) No evidence for the involvement of the multidrug resistance-associated protein and\/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat. AAPS PharmSci 2(3):E26","journal-title":"AAPS PharmSci"},{"issue":"2\u20133","key":"2_CR85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0021-9150(91)90017-W","volume":"87","author":"JN Yuan","year":"1991","unstructured":"Yuan JN, Tsai MY, Hegland J, Hunninghake DB (1991) Effects of fluvastatin (XU 62\u2013320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 87(2\u20133):147\u2013157","journal-title":"Atherosclerosis"},{"key":"2_CR86","unstructured":"Franco D, Henao Y, Monsalve M, Gutierrez F, Hincapie J, Amariles P (2013) Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. Structured review. Farm Hosp 37(6):539\u2013557"},{"key":"2_CR87","doi-asserted-by":"crossref","unstructured":"Climent E, Benaiges D, Pedro-Botet J (2021) Hydrophilic or lipophilic statins? Front Cardiovasc Med 8:687585","DOI":"10.3389\/fcvm.2021.687585"},{"issue":"6","key":"2_CR88","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000506151","volume":"145","author":"SK Kunutsor","year":"2020","unstructured":"Kunutsor SK, Laukkanen JA (2020) Heart failure risk reduction: hydrophilic or lipophilic statins? Cardiology 145(6):384\u2013386","journal-title":"Cardiology"},{"issue":"8","key":"2_CR89","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156800905774932824","volume":"5","author":"J Dulak","year":"2005","unstructured":"Dulak J, Jozkowicz A (2005) Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets 5(8):579\u2013594","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"2_CR90","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","volume":"84","author":"A Corsini","year":"1999","unstructured":"Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84(3):413\u2013428","journal-title":"Pharmacol Ther"},{"issue":"6","key":"2_CR91","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/humu.1380010602","volume":"1","author":"HH Hobbs","year":"1992","unstructured":"Hobbs HH, Brown MS, Goldstein JL (1992) Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1(6):445\u2013466","journal-title":"Hum Mutat"},{"issue":"4","key":"2_CR92","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-8703(00)90033-4","volume":"139","author":"RS Blumenthal","year":"2000","unstructured":"Blumenthal RS (2000) Statins: effective antiatherosclerotic therapy. Am Heart J 139(4):577\u2013583","journal-title":"Am Heart J"},{"key":"2_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR (2014) The pharmacology of statins. Pharmacol Res 88:3\u201311","journal-title":"Pharmacol Res"},{"key":"2_CR94","doi-asserted-by":"crossref","unstructured":"Shamsuddin, Fazil M, Ansari SH, Ali J (2016) Atorvastatin solid dispersion for bioavailability enhancement. J Adv Pharm Technol Res 7(1):22\u201326","DOI":"10.4103\/2231-4040.169873"},{"issue":"5","key":"2_CR95","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1208\/s12249-022-02272-2","volume":"23","author":"D Suram","year":"2022","unstructured":"Suram D, Veerabrahma K (2022) Design and development of solid SMEDDS and liquisolid formulations of lovastatin, for improved drug dissolution and in vivo effects\u2014a pharmacokinetic and pharmacodynamic assessment. AAPS PharmSciTech 23(5):123","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"2_CR96","first-page":"941","volume":"16","author":"M Okamoto","year":"1986","unstructured":"Okamoto M, Sakura E, Shimamoto H, Yokote Y, Hashimoto M, Fujii H et al (1986) Analysis of mitral inflow velocity pattern in relation to left ventricular end-diastolic pressure. J Cardiogr 16(4):941\u2013948","journal-title":"J Cardiogr"},{"issue":"3","key":"2_CR97","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1021\/acsbiomaterials.7b00871","volume":"4","author":"K Wang","year":"2018","unstructured":"Wang K, Yu C, Liu Y, Zhang W, Sun Y, Chen Y (2018) Enhanced antiatherosclerotic efficacy of statin-loaded reconstituted high-density lipoprotein via ganglioside GM1 modification. ACS Biomater Sci Eng 4(3):952\u2013962","journal-title":"ACS Biomater Sci Eng"},{"issue":"13","key":"2_CR98","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","volume":"42","author":"H Lennernas","year":"2003","unstructured":"Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42(13):1141\u20131160","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"2_CR99","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","volume":"25","author":"PD Martin","year":"2003","unstructured":"Martin PD, Warwick MJ, Dane AL, Brindley C, Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25(10):2553\u20132563","journal-title":"Clin Ther"},{"issue":"11 Pt 2","key":"2_CR100","doi-asserted-by":"publisher","first-page":"375S","DOI":"10.1093\/ajh\/6.11.375S","volume":"6","author":"HT Smith","year":"1993","unstructured":"Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT (1993) Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 6(11 Pt 2):375S\u2013382S","journal-title":"Am J Hypertens"},{"issue":"9","key":"2_CR101","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","volume":"11","author":"T Hirota","year":"2015","unstructured":"Hirota T, Ieiri I (2015) Drug\u2013drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol 11(9):1435\u20131447","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2_CR102","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cpt.1599","volume":"107","author":"NS Jones","year":"2020","unstructured":"Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW (2020) Complex DDI by fenebrutinib and the use of transporter endogenous biomarkers to elucidate the mechanism of DDI. Clin Pharmacol Ther 107(1):269\u2013277","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2_CR103","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/pgs-2016-0199","volume":"18","author":"F Jiang","year":"2017","unstructured":"Jiang F, Choi JY, Lee JH, Ryu S, Park ZW, Lee JG et al (2017) The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics 18(5):459\u2013469","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2_CR104","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","volume":"81","author":"YY Lau","year":"2007","unstructured":"Lau YY, Huang Y, Frassetto L, Benet LZ (2007) Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81(2):194\u2013204","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2_CR105","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/molecules21040464","volume":"21","author":"H Cui","year":"2016","unstructured":"Cui H, Wang J, Zhang Q, Dang M, Liu H, Dong Y et al (2016) In vivo and in vitro study on drug\u2013drug interaction of lovastatin and berberine from pharmacokinetic and HepG2 cell metabolism studies. Molecules 21(4):464","journal-title":"Molecules"},{"issue":"10","key":"2_CR106","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/adc.48.10.826-e","volume":"48","author":"B Harcourt","year":"1973","unstructured":"Harcourt B (1973) Proceedings: detection and investigation of homonymous hemianopic visual field defects in young children. Arch Dis Child 48(10):826\u2013827","journal-title":"Arch Dis Child"},{"issue":"4","key":"2_CR107","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/cts.12625","volume":"12","author":"SW Yee","year":"2019","unstructured":"Yee SW, Giacomini MM, Shen H, Humphreys WG, Horng H, Brian W et al (2019) Organic anion transporter polypeptide 1B1 polymorphism modulates the extent of drug\u2013drug interaction and associated biomarker levels in healthy volunteers. Clin Transl Sci 12(4):388\u2013399","journal-title":"Clin Transl Sci"},{"key":"2_CR108","doi-asserted-by":"crossref","unstructured":"Mangia A, Scaglione F, Toniutto P, Pirisi M, Coppola N, Di Perri G et al (2021) Drug\u2013drug interactions in Italian patients with chronic hepatitis C treated with pangenotypic direct acting agents: insights from a real-world study. Int J Environ Res Public Health 18(13)","DOI":"10.3390\/ijerph18137144"},{"key":"2_CR109","doi-asserted-by":"crossref","unstructured":"Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K et al (2019) Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet 44(6):747\u2013759","DOI":"10.1007\/s13318-019-00577-5"},{"issue":"3","key":"2_CR110","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.116.234914","volume":"358","author":"Y Lai","year":"2016","unstructured":"Lai Y, Mandlekar S, Shen H, Holenarsipur VK, Langish R, Rajanna P et al (2016) Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug\u2013drug interactions mediated by organic anion transporting polypeptide inhibition. J Pharmacol Exp Ther 358(3):397\u2013404","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"2_CR111","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.xphs.2017.03.027","volume":"106","author":"HF Wu","year":"2017","unstructured":"Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L et al (2017) Rosuvastatin pharmacokinetics in Asian and white subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions. J Pharm Sci 106(9):2751\u20132757","journal-title":"J Pharm Sci"},{"issue":"2","key":"2_CR112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/QAI.0b013e318251addb","volume":"60","author":"RE Morgan","year":"2012","unstructured":"Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM (2012) Effects of steady-state lopinavir\/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 60(2):158\u2013164","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2_CR113","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1517\/17425255.2014.851667","volume":"10","author":"M Hu","year":"2014","unstructured":"Hu M, Tomlinson B (2014) Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol 10(1):51\u201365","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"2_CR114","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s00228-013-1554-0","volume":"69","author":"Y Chen","year":"2013","unstructured":"Chen Y, Zhang W, Huang WH, Tan ZR, Wang YC, Huang X et al (2013) Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur J Clin Pharmacol 69(11):1933\u20131938","journal-title":"Eur J Clin Pharmacol"},{"key":"2_CR115","doi-asserted-by":"crossref","unstructured":"Garnett WR (1994) The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitor. Clin Cardiol 17(S4):IV-3\u2013IV-10","DOI":"10.1002\/clc.4960171603"},{"issue":"14","key":"2_CR116","doi-asserted-by":"publisher","first-page":"3D","DOI":"10.1016\/0002-9149(94)90626-2","volume":"73","author":"CB Blum","year":"1994","unstructured":"Blum CB (1994) Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 73(14):3D\u201311D","journal-title":"Am J Cardiol"},{"issue":"15","key":"2_CR117","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/ajhp\/52.15.1639","volume":"52","author":"WR Garnett","year":"1995","unstructured":"Garnett WR (1995) Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 52(15):1639\u20131645","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"2_CR118","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41401-018-0039-1","volume":"39","author":"D Feng","year":"2018","unstructured":"Feng D, Ge C, Tan ZY, Sun JG, Xie Y, Yao L et al (2018) Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Acta Pharmacol Sin 39(11):1804\u20131815","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"2_CR119","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s00726-014-1772-5","volume":"46","author":"G Corsetti","year":"2014","unstructured":"Corsetti G, D\u2019Antona G, Ruocco C, Stacchiotti A, Romano C, Tedesco L et al (2014) Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidney. Amino Acids 46(9):2189\u20132203","journal-title":"Amino Acids"},{"key":"2_CR120","doi-asserted-by":"crossref","unstructured":"Al-Asmari AK, Ullah Z, Al-Sabaan F, Tariq M, Al-Eid A, Al-Omani SF (2015) Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. Eur J Drug Metab Pharmacokinet 40(1):87\u201394","DOI":"10.1007\/s13318-014-0183-z"},{"issue":"2","key":"2_CR121","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4062\/biomolther.2015.089","volume":"24","author":"HK Choi","year":"2016","unstructured":"Choi HK, Won EK, Choung SY (2016) Effect of coenzyme Q10 supplementation in statin-treated obese rats. Biomol Ther (Seoul) 24(2):171\u2013177","journal-title":"Biomol Ther (Seoul)"},{"key":"2_CR122","doi-asserted-by":"crossref","unstructured":"Dogay Us G, Mushtaq S (2022) N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial. Lipids Health Dis 21(1):84","DOI":"10.1186\/s12944-022-01686-y"},{"issue":"1","key":"2_CR123","first-page":"34","volume":"46","author":"D Shang","year":"2016","unstructured":"Shang D, Deng S, Yao Z, Wang Z, Ni X, Zhang M et al (2016) The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects. Xenobiotica 46(1):34\u201339","journal-title":"Xenobiotica"},{"issue":"2","key":"2_CR124","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.atherosclerosis.2013.09.031","volume":"231","author":"Z Sternberg","year":"2013","unstructured":"Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S et al (2013) Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis 231(2):411\u2013420","journal-title":"Atherosclerosis"},{"issue":"1","key":"2_CR125","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","volume":"62","author":"TG Simon","year":"2015","unstructured":"Simon TG, King LY, Zheng H, Chung RT (2015) Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol 62(1):18\u201323","journal-title":"J Hepatol"},{"issue":"19","key":"2_CR126","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/eurheartj\/ehy014","volume":"39","author":"JS Biedermann","year":"2018","unstructured":"Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC et al (2018) Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J 39(19):1740\u20131747","journal-title":"Eur Heart J"},{"issue":"2","key":"2_CR127","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/jth.14364","volume":"17","author":"FA Orsi","year":"2019","unstructured":"Orsi FA, Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, van Hylckama VA et al (2019) Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. J Thromb Haemost 17(2):319\u2013328","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2_CR128","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjh.16648","volume":"190","author":"S Schol-Gelok","year":"2020","unstructured":"Schol-Gelok S, de Maat MPM, Biedermann JS, van Gelder T, Leebeek FWG, Lijfering WM et al (2020) Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. Br J Haematol 190(6):916\u2013922","journal-title":"Br J Haematol"},{"issue":"4","key":"2_CR129","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/jth.15626","volume":"20","author":"C Ramberg","year":"2022","unstructured":"Ramberg C, Hindberg K, Biedermann JS, Cannegieter SC, van der Meer FJ, Snir O et al (2022) Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: a randomized controlled trial. J Thromb Haemost 20(4):877\u2013887","journal-title":"J Thromb Haemost"},{"key":"2_CR130","doi-asserted-by":"crossref","unstructured":"Hsu C, Brahmandam A, Brownson KE, Huynh N, Reynolds J, Lee AI et al (2019) Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis. J Vasc Surg Venous Lymphat Disord 7(2):169\u2013175.e4","DOI":"10.1016\/j.jvsv.2018.10.020"},{"key":"2_CR131","doi-asserted-by":"crossref","unstructured":"San Norberto EM, Gastambide MV, Taylor JH, Garcia-Saiz I, Vaquero C (2016) Effects of rosuvastatin as an adjuvant treatment for deep vein thrombosis. Vasa 45(2):133\u2013140","DOI":"10.1024\/0301-1526\/a000507"},{"issue":"7","key":"2_CR132","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12944","volume":"48","author":"S Schol-Gelok","year":"2018","unstructured":"Schol-Gelok S, van der Hulle T, Biedermann JS, van Gelder T, Klok FA, van der Pol LM et al (2018) Clinical effects of antiplatelet drugs and statins on D-dimer levels. Eur J Clin Invest 48(7):e12944","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"2_CR133","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/clc.23833","volume":"45","author":"T Alirezaei","year":"2022","unstructured":"Alirezaei T, Sattari H, Irilouzadian R (2022) Significant decrease in plasmad-dimer levels and mean platelet volume after a 3-month treatment with rosuvastatin in patients with venous thromboembolism. Clin Cardiol 45(7):717\u2013722","journal-title":"Clin Cardiol"},{"issue":"1","key":"2_CR134","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/hrt.2003.027110","volume":"91","author":"D Tousoulis","year":"2005","unstructured":"Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C et al (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91(1):27\u201331","journal-title":"Heart"},{"issue":"2","key":"2_CR135","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijcard.2007.06.030","volume":"128","author":"E Ordulu","year":"2008","unstructured":"Ordulu E, Erdogan O (2008) Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. Int J Cardiol 128(2):282\u2013284","journal-title":"Int J Cardiol"},{"issue":"3","key":"2_CR136","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijcard.2005.02.011","volume":"106","author":"D Tousoulis","year":"2006","unstructured":"Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniades C, Katsi V, Stefanadis C (2006) Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina. Int J Cardiol 106(3):333\u2013337","journal-title":"Int J Cardiol"},{"issue":"2","key":"2_CR137","first-page":"344","volume":"106","author":"F Mobarrez","year":"2011","unstructured":"Mobarrez F, He S, Broijersen A, Wiklund B, Antovic A, Antovic J et al (2011) Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 106(2):344\u2013352","journal-title":"Thromb Haemost"},{"issue":"1","key":"2_CR138","first-page":"41","volume":"88","author":"M Cortellaro","year":"2002","unstructured":"Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E et al (2002) Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 88(1):41\u201347","journal-title":"Thromb Haemost"},{"issue":"2","key":"2_CR139","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11239-014-1142-x","volume":"39","author":"TR Sexton","year":"2015","unstructured":"Sexton TR, Wallace EL, Macaulay TE, Charnigo RJ, Evangelista V, Campbell CL et al (2015) The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis 39(2):186\u2013195","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2_CR140","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/jcbfm.2009.59","volume":"29","author":"MD Vergouwen","year":"2009","unstructured":"Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES et al (2009) Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 29(8):1444\u20131453","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"2_CR141","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/S0735-1097(99)00018-2","volume":"33","author":"G Dangas","year":"1999","unstructured":"Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH et al (1999) Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 33(5):1294\u20131304","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2_CR142","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10557-005-2160-x","volume":"19","author":"E Atalar","year":"2005","unstructured":"Atalar E, Coskun S, Haznedaroglu IC, Yucel N, Ozer N, Sivri B et al (2005) Immediate effects of fluvastain on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes. Cardiovasc Drugs Ther 19(3):177\u2013181","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"2_CR143","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0021-9150(00)00397-X","volume":"153","author":"U Rauch","year":"2000","unstructured":"Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K et al (2000) Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 153(1):181\u2013189","journal-title":"Atherosclerosis"},{"issue":"5","key":"2_CR144","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1538-7836.2006.01882.x","volume":"4","author":"A Undas","year":"2006","unstructured":"Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A (2006) Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4(5):1029\u20131036","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2_CR145","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.thromres.2009.06.021","volume":"125","author":"M Pastuszczak","year":"2010","unstructured":"Pastuszczak M, Kotlarz A, Mostowik M, Zalewski J, Zmudka K, Undas A (2010) Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res 125(5):382\u2013386","journal-title":"Thromb Res"},{"issue":"4","key":"2_CR146","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0049-3848(02)00034-8","volume":"105","author":"I Seljeflot","year":"2002","unstructured":"Seljeflot I, Tonstad S, Hjermann I, Arnesen H (2002) Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 105(4):285\u2013290","journal-title":"Thromb Res"},{"key":"2_CR147","doi-asserted-by":"crossref","unstructured":"Velarde GP, Choudhary N, Bravo-Jaimes K, Smotherman C, Sherazi S, Kraemer DF (2021) Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome. Nutr Metab Cardiovasc Dis 31(2):634\u2013640","DOI":"10.1016\/j.numecd.2020.10.002"},{"issue":"2","key":"2_CR148","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1089\/met.2008.0012","volume":"6","author":"L Wang","year":"2008","unstructured":"Wang L, Rockwood J, Zak D, Devaraj S, Jialal I (2008) Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Metab Syndr Relat Disord 6(2):149\u2013152","journal-title":"Metab Syndr Relat Disord"},{"key":"2_CR149","doi-asserted-by":"crossref","unstructured":"Van De Ree MA, De Maat MP, Kluft C, Meinders AE, Princen HM, Huisman MV et al (2003) Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. J Thromb Haemost 1(8):1753\u20131757","DOI":"10.1046\/j.1538-7836.2003.00357.x"},{"issue":"3","key":"2_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032894","volume":"7","author":"A Macchia","year":"2012","unstructured":"Macchia A, Laffaye N, Comignani PD, Cornejo Pucci E, Igarzabal C, Scazziota AS et al (2012) Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PLoS ONE 7(3):e32894","journal-title":"PLoS ONE"},{"issue":"3","key":"2_CR151","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/j.thromres.2010.05.023","volume":"126","author":"S Tehrani","year":"2010","unstructured":"Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U et al (2010) Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 126(3):e225\u2013e231","journal-title":"Thromb Res"},{"issue":"2","key":"2_CR152","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/diacare.27.2.468","volume":"27","author":"DW Sommeijer","year":"2004","unstructured":"Sommeijer DW, MacGillavry MR, Meijers JC, Van Zanten AP, Reitsma PH, Ten Cate H (2004) Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27(2):468\u2013473","journal-title":"Diabetes Care"},{"issue":"6","key":"2_CR153","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.metabol.2010.02.011","volume":"59","author":"AL Kater","year":"2010","unstructured":"Kater AL, Batista MC, Ferreira SR (2010) Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 59(6):921\u2013926","journal-title":"Metabolism"},{"issue":"1\u20133","key":"2_CR154","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejphar.2004.04.025","volume":"493","author":"J Skrha","year":"2004","unstructured":"Skrha J, Stulc T, Hilgertova J, Weiserova H, Kvasnicka J, Ceska R (2004) Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol 493(1\u20133):183\u2013189","journal-title":"Eur J Pharmacol"},{"issue":"3\u20134","key":"2_CR155","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000341909","volume":"92","author":"R Krysiak","year":"2013","unstructured":"Krysiak R, Okopien B (2013) Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. Pharmacology 92(3\u20134):187\u2013190","journal-title":"Pharmacology"},{"issue":"3","key":"2_CR156","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1472-8206.2011.00932.x","volume":"26","author":"R Krysiak","year":"2012","unstructured":"Krysiak R, Zmuda W, Okopien B (2012) The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol 26(3):424\u2013431","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"2_CR157","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1160\/TH05-01-0067","volume":"94","author":"A Undas","year":"2005","unstructured":"Undas A, Celinska-Lowenhoff M, Domagala TB, Iwaniec T, Dropinski J, Lowenhoff T et al (2005) Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 94(1):193\u2013199","journal-title":"Thromb Haemost"},{"key":"2_CR158","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.atherosclerosis.2016.12.019","volume":"257","author":"O Panes","year":"2017","unstructured":"Panes O, Gonzalez C, Hidalgo P, Valderas JP, Acevedo M, Contreras S et al (2017) Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 257:164\u2013171","journal-title":"Atherosclerosis"},{"issue":"6","key":"2_CR159","first-page":"378","volume":"11","author":"L Puccetti","year":"2001","unstructured":"Puccetti L, Bruni F, Bova G, Cercignani M, Palazzuoli A, Console E et al (2001) Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 11(6):378\u2013387","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"2_CR160","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1345\/aph.1C189","volume":"37","author":"G Kadikoylu","year":"2003","unstructured":"Kadikoylu G, Yukselen V, Yavasoglu I, Bolaman Z (2003) Hemostatic effects of atorvastatin versus simvastatin. Ann Pharmacother 37(4):478\u2013484","journal-title":"Ann Pharmacother"},{"issue":"7","key":"2_CR161","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/jth.15282","volume":"19","author":"AK Rao","year":"2021","unstructured":"Rao AK, Del Carpio-Cano F, Janapati S, Zhao H, Voelker H, Lu X et al (2021) Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (simvastatin in the prevention of COPD exacerbations) trial. J Thromb Haemost 19(7):1709\u20131717","journal-title":"J Thromb Haemost"},{"key":"2_CR162","doi-asserted-by":"crossref","unstructured":"Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M et al (2009) Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 102(6):1176\u20131182","DOI":"10.1160\/TH09-02-0118"},{"issue":"6","key":"2_CR163","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/jth.14004","volume":"16","author":"S Ades","year":"2018","unstructured":"Ades S, Douce D, Holmes CE, Cory S, Prior S, Butenas S et al (2018) Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. J Thromb Haemost 16(6):1099\u20131106","journal-title":"J Thromb Haemost"},{"key":"2_CR164","doi-asserted-by":"crossref","unstructured":"Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A et al (2006) Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol 17(12 Suppl 3):S231\u2013S235","DOI":"10.1681\/ASN.2006080938"},{"key":"2_CR165","first-page":"75","volume":"318","author":"V Netyazhenko","year":"2021","unstructured":"Netyazhenko V, Bazhenova N (2021) The influence of hypercholesterolemia and concomitant statin therapy on the state of platelet-plasma hemostasis in patients with essential hypertension and non-alcoholic fatty liver disease. Georgian Med News 318:75\u201381","journal-title":"Georgian Med News"},{"key":"2_CR166","doi-asserted-by":"crossref","unstructured":"Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES (2014) High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complicat 28(3):365\u2013369","DOI":"10.1016\/j.jdiacomp.2014.01.006"},{"issue":"9","key":"2_CR167","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I (2020) An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 16(9):809\u2013822","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2_CR168","doi-asserted-by":"crossref","unstructured":"Valladales-Restrepo LF, Medina-Morales DA, Giraldo-Giraldo C, Machado-Alba JE (2021) Prescription of statins and pharmacokinetic interactions in Colombian patients. Expert Opin Drug Metab Toxicol 17(5):627\u2013634","DOI":"10.1080\/17425255.2021.1908261"},{"key":"2_CR169","doi-asserted-by":"crossref","unstructured":"Strachan A (2018) A concise summary of coagulation in liver disease. J Anest Inten Care Med 6(1)","DOI":"10.19080\/JAICM.2018.06.555679"},{"key":"2_CR170","doi-asserted-by":"crossref","unstructured":"Hou Y, Carrim N, Wang Y, Gallant RC, Marshall A, Ni H (2015) Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. J Biomed Res 29","DOI":"10.7555\/JBR.29.20150121"},{"issue":"10","key":"2_CR171","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.5603\/KP.2013.0259","volume":"71","author":"N Sivri","year":"2013","unstructured":"Sivri N, Tekin G, Yalta K, Aksoy Y, Senen K, Yetkin E (2013) Statins decrease mean platelet volume irrespective of cholesterol lowering effect. Kardiol Pol 71(10):1042\u20131047","journal-title":"Kardiol Pol"},{"issue":"1","key":"2_CR172","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11239-007-0154-1","volume":"27","author":"E Tirnaksiz","year":"2009","unstructured":"Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y (2009) Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 27(1):24\u201328","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2_CR173","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1365-2362.2012.02661.x","volume":"42","author":"B Luzak","year":"2012","unstructured":"Luzak B, Rywaniak J, Stanczyk L, Watala C (2012) Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition. Eur J Clin Invest 42(8):864\u2013872","journal-title":"Eur J Clin Invest"},{"key":"2_CR174","unstructured":"Chu LX, Zhou SX, Yang F, Qin YQ, Liang ZS, Mo CG et al (2016) Pravastatin and C reactive protein modulate protease-activated receptor-1 expression in vitro blood platelets. Cell Mol Biol (Noisy-le-grand) 62(2):75\u201380"},{"issue":"5","key":"2_CR175","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/09537104.2020.1792434","volume":"32","author":"N Hannachi","year":"2021","unstructured":"Hannachi N, Fournier PE, Martel H, Habib G, Camoin-Jau L (2021) Statins potentiate the antibacterial effect of platelets on Staphylococcus aureus. Platelets 32(5):671\u2013676","journal-title":"Platelets"},{"issue":"7","key":"2_CR176","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1161\/01.ATV.0000168909.44877.a7","volume":"25","author":"AC Jansen","year":"2005","unstructured":"Jansen AC, van Aalst-Cohen ES, Tanck MW, Cheng S, Fontecha MR, Li J et al (2005) Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 25(7):1475\u20131481","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2_CR177","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1172\/JCI58969","volume":"122","author":"AP Owens 3rd","year":"2012","unstructured":"Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L et al (2012) Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. J Clin Invest 122(2):558\u2013568","journal-title":"J Clin Invest"},{"issue":"4","key":"2_CR178","first-page":"298","volume":"67","author":"B Vallet","year":"2001","unstructured":"Vallet B (2001) Microthrombosis in sepsis. Minerva Anestesiol 67(4):298\u2013301","journal-title":"Minerva Anestesiol"},{"key":"2_CR179","doi-asserted-by":"crossref","unstructured":"La Mura V, Gagliano N, Arnaboldi F, Sartori P, Procacci P, Denti L et al (2022) Simvastatin prevents liver microthrombosis and sepsis induced coagulopathy in a rat model of endotoxemia. Cells 11(7)","DOI":"10.3390\/cells11071148"},{"issue":"1","key":"2_CR180","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11596-022-2526-3","volume":"42","author":"M Xu","year":"2022","unstructured":"Xu M, Luo LL, Du MY, Tang L, Zhou J, Hu Y et al (2022) Simvastatin improves outcomes of endotoxin-induced coagulopathy by regulating intestinal microenvironment. Curr Med Sci 42(1):26\u201338","journal-title":"Curr Med Sci"},{"issue":"8567","key":"2_CR181","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0140-6736(87)91481-4","volume":"2","author":"MW Radomski","year":"1987","unstructured":"Radomski MW, Palmer RM, Moncada S (1987) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2(8567):1057\u20131058","journal-title":"Lancet"},{"issue":"3","key":"2_CR182","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/00003246-199703000-00014","volume":"25","author":"M Jourdain","year":"1997","unstructured":"Jourdain M, Tournoys A, Leroy X, Mangalaboyi J, Fourrier F, Goudemand J et al (1997) Effects of N omega-nitro-L-arginine methyl ester on the endotoxin-induced disseminated intravascular coagulation in porcine septic shock. Crit Care Med 25(3):452\u2013459","journal-title":"Crit Care Med"},{"issue":"4","key":"2_CR183","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003327","volume":"5","author":"CP Hsu","year":"2016","unstructured":"Hsu CP, Zhao JF, Lin SJ, Shyue SK, Guo BC, Lu TM et al (2016) Asymmetric dimethylarginine limits the efficacy of simvastatin activating endothelial nitric oxide synthase. J Am Heart Assoc 5(4):e003327","journal-title":"J Am Heart Assoc"},{"key":"2_CR184","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1423-0127-18-26","volume":"18","author":"WS Lian","year":"2011","unstructured":"Lian WS, Lin H, Cheng WT, Kikuchi T, Cheng CF (2011) Granulocyte-CSF induced inflammation-associated cardiac thrombosis in iron loading mouse heart and can be attenuated by statin therapy. J Biomed Sci 18:26","journal-title":"J Biomed Sci"},{"key":"2_CR185","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.biopha.2018.04.118","volume":"103","author":"RP Mason","year":"2018","unstructured":"Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T (2018) Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother 103:1231\u20131237","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2_CR186","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/AC.71.1.3132094","volume":"71","author":"F Zhao","year":"2016","unstructured":"Zhao F, Ji Z, Chi J, Tang W, Zhai X, Meng L et al (2016) Effects of Chinese yellow wine on nitric oxide synthase and intercellular adhesion molecule-1 expressions in rat vascular endothelial cells. Acta Cardiol 71(1):27\u201334","journal-title":"Acta Cardiol"},{"issue":"1","key":"2_CR187","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5603\/CJ.2012.0005","volume":"19","author":"K Stach","year":"2012","unstructured":"Stach K, Nguyen XD, Lang S, Elmas E, Weiss C, Borggrefe M et al (2012) Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand. Cardiol J 19(1):20\u201328","journal-title":"Cardiol J"},{"issue":"1","key":"2_CR188","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/sj.bjp.0704454","volume":"135","author":"F Wiesbauer","year":"2002","unstructured":"Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J (2002) HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 135(1):284\u2013292","journal-title":"Br J Pharmacol"},{"issue":"11","key":"2_CR189","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood.V106.11.1021.1021","volume":"106","author":"DJ Dietzen","year":"2005","unstructured":"Dietzen DJ (2005) The antithrombotic effect of atorvastatin is mediated by decreased plasma membrane exposure of phosphatidylserine. Blood 106(11):1021","journal-title":"Blood"},{"key":"2_CR190","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-015-0508-y","volume":"13","author":"H Abou-Saleh","year":"2015","unstructured":"Abou-Saleh H, Hachem A, Yacoub D, Gillis MA, Merhi Y (2015) Endothelial progenitor cells inhibit platelet function in a P-selectin-dependent manner. J Transl Med 13:142","journal-title":"J Transl Med"},{"issue":"22","key":"2_CR191","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1161\/CIRCULATIONAHA.109.894642","volume":"120","author":"H Abou-Saleh","year":"2009","unstructured":"Abou-Saleh H, Yacoub D, Theoret JF, Gillis MA, Neagoe PE, Labarthe B et al (2009) Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation 120(22):2230\u20132239","journal-title":"Circulation"},{"issue":"1\u20132","key":"2_CR192","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jns.2012.04.015","volume":"319","author":"B Wang","year":"2012","unstructured":"Wang B, Sun L, Tian Y, Li Z, Wei H, Wang D et al (2012) Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats. J Neurol Sci 319(1\u20132):117\u2013123","journal-title":"J Neurol Sci"}],"container-title":["Advances in Experimental Medicine and Biology","Advances in Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-26163-3_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:05:29Z","timestamp":1682323529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-26163-3_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031261626","9783031261633"],"references-count":192,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-26163-3_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"25 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}